1. Home
  2. IOVA vs IART Comparison

IOVA vs IART Comparison

Compare IOVA & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • IART
  • Stock Information
  • Founded
  • IOVA 2007
  • IART 1989
  • Country
  • IOVA United States
  • IART United States
  • Employees
  • IOVA N/A
  • IART N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • IART Medical/Dental Instruments
  • Sector
  • IOVA Health Care
  • IART Health Care
  • Exchange
  • IOVA Nasdaq
  • IART Nasdaq
  • Market Cap
  • IOVA 771.4M
  • IART 922.4M
  • IPO Year
  • IOVA N/A
  • IART 1995
  • Fundamental
  • Price
  • IOVA $1.88
  • IART $12.59
  • Analyst Decision
  • IOVA Buy
  • IART Hold
  • Analyst Count
  • IOVA 10
  • IART 9
  • Target Price
  • IOVA $12.22
  • IART $19.43
  • AVG Volume (30 Days)
  • IOVA 10.4M
  • IART 1.2M
  • Earning Date
  • IOVA 08-07-2025
  • IART 07-28-2025
  • Dividend Yield
  • IOVA N/A
  • IART N/A
  • EPS Growth
  • IOVA N/A
  • IART N/A
  • EPS
  • IOVA N/A
  • IART N/A
  • Revenue
  • IOVA $212,679,000.00
  • IART $1,624,308,000.00
  • Revenue This Year
  • IOVA $86.62
  • IART $5.56
  • Revenue Next Year
  • IOVA $69.95
  • IART $4.41
  • P/E Ratio
  • IOVA N/A
  • IART N/A
  • Revenue Growth
  • IOVA 11070.12
  • IART 6.19
  • 52 Week Low
  • IOVA $1.64
  • IART $11.06
  • 52 Week High
  • IOVA $12.51
  • IART $32.66
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 47.47
  • IART 46.20
  • Support Level
  • IOVA $1.68
  • IART $12.59
  • Resistance Level
  • IOVA $2.02
  • IART $13.69
  • Average True Range (ATR)
  • IOVA 0.11
  • IART 0.63
  • MACD
  • IOVA 0.03
  • IART 0.13
  • Stochastic Oscillator
  • IOVA 61.42
  • IART 55.43

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Share on Social Networks: